Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

Jean‐Jacques Kiladjian, Pierre Zachée, Masayuki Hino, Fabrizio Pane, Tamás Masszi, Claire Harrison, Ruben A. Mesa, Carole B. Miller, Francesco Passamonti, Simon Durrant, Martin Grießhammer, Keita Kirito, Carlos Besses, Beatriz Moiraghi, Elisa Rumi, Vittorio Rosti, Igor Wolfgang Blau, Nathalie Francillard, Tuochuan Dong, Monika Wroclawska, Alessandro M. Vannucchi, Srđan Verstovšek